LGALS3 signaling and macrophage ferroptosis in steatohepatitis

Table 1 Translational deliverables for evaluating LGALS3-TRAF6-GPX4 axis in metabolic dysfunction-associated steatohepatitis

Domain	Specimen/system	Assay/readout	Translational purpose	Decision impact
Disease staging and baseline risk	Serum/plasma; elastography platform	FIB-4; ELF where available; VCTE; FAST or other validated composite NITs	Define baseline disease severity and enrich for patients with active steatohepatitis and clinically meaningful fibrosis	Trial enrichment; subgroup definition; baseline comparability
Exploratory target engagement	Liver tissue; serum/plasma; macrophage assay systems	Liver LGALS3/TRAF6/GPX4 by immunohistochemistry or immunoblotting; circulating LGALS3; oxidative/iron-stress readouts such as lipid peroxidation and iron-related indices	Determine whether the proposed axis is modulated in vivo or ex vivo after intervention	Proof-of-mechanism; early pharmacodynamic assessment
Potency definition	Standardized macrophage-based bioassay	LGALS3/TRAF6 pathway activity under defined stimulation; GPX4-related redox and iron-handling readouts; predefined acceptance range for active batches	Define what constitutes an active and comparable batch of the final formulation	Batch release; comparability across production lots and study sites
Chemistry and quality control	Raw materials and finished product	Botanical authentication; chromatographic fingerprinting; prioritized marker/Q-marker panel; contaminant and stability testing	Link chemical consistency to biological consistency and manufacturing control	Regulatory readiness; manufacturing scalability; batch-to-batch reproducibility
Human relevance and model bridging	Primary human Kupffer cells; precision-cut liver slices; metabolically relevant animal models	Directional validation of axis modulation across human-relevant systems and obesity-linked disease models	Reduce the risk that the mechanism is restricted to a single mouse model or immortalized macrophage line	External validity; confidence for clinical translation
Clinical positioning and safety	Clinical development plan; medication-exposure context	Predefined add-on/sequence/combination hypothesis; herb-drug interaction assessment; liver-specific safety monitoring	Clarify where the intervention could fit in the current MASH treatment landscape and whether chronic use is feasible	Clinical adoption pathway; risk mitigation; go/no-go decisions
Durability and fibrosis-linked benefit	Longitudinal animal studies and, later, clinical follow-up datasets	Repeated histology where appropriate; fibrosis-related NIT trajectories; relapse/stressor robustness	Distinguish transient biochemical improvement from sustained fibrosis-relevant benefit	Phase-transition value; long-term development relevance

ELF: Enhanced liver fibrosis test; FAST: FibroScan-aspartate aminotransferase score; FIB-4: Fibrosis-4; NIT: Noninvasive test; MASH: Metabolic dysfunction-associated steatohepatitis; Q-marker: Quality marker; VCTE: Vibration-controlled transient elastography.